Combined Pegaptanib sodium (Macugen) and photodynamic therapy in predominantly classic juxtafoveal choroidal neovascularisation in age related macular degeneration

Calvo-González, C; Reche-Frutos, J; Donate-López, J.; García‐Feijoó, Julián; Leila, Mahmoud; Fernández-Pérez, Cristina; García–Sánchez, J.

doi:10.1136/bjo.2007.128942

Cited by 12 publications

(9 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A small open-label study of seven patients treated with PDT followed by intravitreal pegaptanib 48 h later has recently been reported. 31 In this study, retreatment was indicated with pegaptanib every 6 weeks and with PDT every 12 weeks if fl uorescein angiography showed leakage or OCT detected intraretinal oedema. At 24 weeks, patients had an insignifi cant decrease in mean best-corrected visual acuity from 60.4 letters at baseline to 55.2 letters.…”

Section: Anti-vegf Therapy In Combination With Pdtmentioning

confidence: 97%

“…Although these results are generally poor, the authors suggested that larger-scale controlled studies are required to ascertain whether PDT can reduce the number of intravitreal injections, and which antiangiogenic agent would provide the most potent combination with PDT. 31 Ranibizumab has also been investigated in combination with PDT. The FOCUS study was a 2-year multicentre, randomised, single-masked, controlled study to examine the safety and effi cacy of ranibizumab in combination with verteporfi n PDT in 162 patients with neovascular AMD.…”

Section: Anti-vegf Therapy In Combination With Pdtmentioning

confidence: 99%

See 1 more Smart Citation

Current status of anti-vascular endothelial growth factor therapy in Europe

Wolf

2008

Jpn J Ophthalmol

View full text Add to dashboard Cite

Vascular endothelial growth factor (VEGF) is an important modulator of angiogenesis, and has been implicated in the pathology of a number of conditions, including age-related macular degeneration (AMD), diabetic retinopathy, and cancer. AMD is a progressive disease of the macula and the third major cause of blindness worldwide. If not treated appropriately, AMD can progress rapidly, causing legal blindness within months of the second eye becoming affected. Until recently, the treatment options for AMD have been limited, with photodynamic therapy (PDT) the mainstay treatment. Although PDT is effective at slowing disease progression, it rarely results in improved vision. Pegaptanib and ranibizumab are both anti-VEGF therapies licensed for the treatment of neovascular AMD in Europe; however, these drugs are not yet available in Japan. This article reviews the available clinical data on anti-VEGF therapies for the treatment of neovascular AMD in Europe, and considers the future of this exciting therapy.

show abstract

Section: Anti-vegf Therapy In Combination With Pdtmentioning

confidence: 97%

Section: Anti-vegf Therapy In Combination With Pdtmentioning

confidence: 99%

Current status of anti-vascular endothelial growth factor therapy in Europe

Wolf

2008

Jpn J Ophthalmol

View full text Add to dashboard Cite

show abstract

“…Unlike the polymer-protein conjugates, where the last FDA approval covered different diseases [126][127][128] such as hepatitis C [131], gout [132], acromegaly [133][134][135], neutropenia [136][137][138], Crohn's disease [139], renal anemia [140], and age-related macular degeneration [141][142][143], the research on polymer-drug conjugates has been focused on cancer treatment, with at least 20 conjugates currently in clinical trials (some of them in discontinued status) [127,130,144]. They are based on the traditional cytotoxic drugs (e.g.…”

Section: Polymer Therapeuticsmentioning

confidence: 99%

Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy

Pérez-Herrero

Fernández‐Medarde

2015

European Journal of Pharmaceutics and Biopharmaceutics

1,380

754

View full text Add to dashboard Cite

Cancer is the second worldwide cause of death, exceeded only by cardiovascular diseases. It is characterized by uncontrolled cell proliferation and an absence of cell death that, except for hematological cancers, generates an abnormal cell mass or tumor. This primary tumor grows thanks to new vasculatization and, in time, adquires metastatic potential and spreads to other body sites, which causes metastasis and finally death. Cancer is caused by damage or mutations in the genetic material of the cells due to environmental or inherited factors. While surgery and radiotherapy are the primary treatment used for local and non-metastatic cancers, anti-cancer drugs (chemotherapy, hormone and biological therapies) are the choice currently used in metastasic cancers. Chemotherapy is based on the inhibition of the division of rapidly growing cells, which is a characteristic of the cancerous cells, but unfortunately, it also affects normal cells with fast proliferation rates, like the hair follicles, bone marrow and gastrointestinal tract cells, generating the characteristic side effects of chemotherapy. The indiscriminate destruction of normal cells, the toxicity of conventional chemotherapeutic Código de campo cambiado

show abstract

“…Re cently,Cal vo-Gon za lesetal.ha vere por ted po orres pon setocom bi nedthe rapyusingPDTand Pe gap ta nibinthe irsevenca sesofpre do mi nantly clas sicjux ta fo ve alCNVMdu etoAMD. 15 Thiswas al sotheca seinourca seswithpre do mi nantlyclassi calCNVM.Manystu di esha vere por tedbet tervisu al re sults and less ret re at ment ne ed in ca ses re ce i vingcom bi nedFDTandeit herra ni bi zu mab or be va ci zu mab com pa red to ca ses tre a ted with mo not he rapyalo ne. [16][17][18] ItisknownthatPDTincre a sestheVEGFle velsinCNVM.…”

Section: Discussionmentioning

confidence: 98%

Pegaptanib Versus Combined Pegaptanib and Photodynamic Therapy for Neovascular Age-Related Macular Degeneration

Akduman¹,

Kaderli²,

Kim³

et al. 2010

Turkiye Klinikleri J Med Sci

View full text Add to dashboard Cite

ABS TRACTOb jec ti ve: Theaimofthisstudyistore vi ewourex pe ri en cewithPe gap ta nibinpa tientswithne o vas cu larage-re la tedma cu larde ge ne ra ti on(AMD)andtode ter mi newhet herout comeswo uldbeim pro vedbycom bi ningPe gap ta nibwithpho tody na micthe rapy(PDT).Ma te ri al andMet hods:Ins ti tu ti o nal,ret ros pec ti veca sese ri es.Thechartsof20pa ti entswithne o vas cu lar AMDwhore ce i vedPe gap ta nibmo not he rapyorcom bi nedocu larPDTwithVer te por finwe reretros pec ti velyre vi e wed.Ma inout co meme a su rescon sis tedofthenum beroftre at mentsapp li ed, Snel lenbest-cor rec tedvi su alacu ity(BCVA),an gi og rap hicle si oncha rac te ris ticsandcen terfi eld thick ness(CFT)inop ti calco he ren ceto mog raphy(OCT).Re sults:Ave ra gefol low-upti mewas7.7 months(ran ge,3-12months).Tenpa ti ents(50%)we reinPe gap ta nibmo not he rapygro up(Gro up A)and10pa ti entswe reincom bi na ti onthe rapywithPDTgro up(Gro upB).Pa ti entsinbothgroupsre ce i ved2to9(me an,5.2)Pe gap ta nibin jec ti ons.Gro upBre ce i ved1to4(me an,1.8)PDTtreat ments.Ini ti alBCVAran gedfrom20/50to20/3200(me an,20/509),fi nalBCVAran gedfrom20/70 to20/3200(me an,20/759).Ingro upA,theme anini ti alandfi nalBCVAwe re20/650and20/617, res pec ti vely(p=0.590).Thecor res pon dingnum bersingro upBwe re20/398and20/1060,res pecti vely(p=0.062).Fo urofthe10eyes(40%)inGro upBlostthreeli nesormo re.No neoftheeyes inGro upAlostthreeli nesormo revi si on(p=0.087).The rewasne it hersig ni fi cantchan geinthe le si onsi ze(p=0.513),norinCFT(315µmto268µm,p=0.99).Conc lu si on:There sultsofthisstudy sug gestthatcom bi nedocu larPDTandPe gap ta nibtre at mentmaynotbesu pe ri ortoPe gap ta nibaloneinpa ti entswithne o vas cu larAMD.Furt herstu di esarene e ded.KeyWords:Cho ro i dalne o vas cu la ri za ti on;pe gap ta nib;ver te por fin ÖZETAmaç:Buça lış ma dane o vas kü leryaşbağımlımakülerdejenerasyon(YBMD)ol gu la rın dauygu la dı ğı mızPe gap ta nibte da vi si ninso nuç la rı nıvekom bi nePe gap ta nibvefotodinamiktedavinin (FDT)olum luet ki si ninolupol ma dı ğı nınaraş tı rıl ma sıamaç lan dı.Ge reçveYön tem ler:Ret ros pektifol guse ri si.Ne o vas kü lerYBMDne de niy letekba şı nave yaFDTilekom bi nePe gap ta nibte da vi siuygu la nan20ol gu nunka yıt la rıret ros pek tifola rakin ce len di.Anaiz lempa ra met re le riola rakuy gu la nan te da visa yı sı,Snel leneniyidü zel til mişgör mekes kin li ği(EİDGK),an ji yog ra fiklez yonözel lik le rive op tikko he rensto mog ra fi desan tralma ku laka lın lı ğı(SMK)de ğer len di ril di.Bul gu lar: Or ta la maizlemsü re si7.7ay dı(3-12ay).Onol gu ya(%50)tekba şı naPe gap ta nib(GrupA)ve10ol gu yadaFDT ilekom bi nete da vi(GrupB)uy gu lan dı.Herikigrup tauy gu la nanPe gap ta niben jek si yonsa yı sı2ile 9ara sın dade ğiş mek tey di(or ta la ma5.2).GrupB'de kiol gu la ra1ile4kez(or ta la ma1.8)FDTuy gulan dı.Te da viön ce siEİDGK20/50ile20/3200ara sın day dı(or ta la ma20/509).Te da vison ra sıöl çü len sonEİDGKise20/70ile20/3200ar sın day dı(or ta la ma20/759).GrupA' dailkvesonEİDGKsı ra sıy -la20/65...

show abstract

Combined Pegaptanib sodium (Macugen) and photodynamic therapy in predominantly classic juxtafoveal choroidal neovascularisation in age related macular degeneration

Abstract: Predominantly classic juxtafoveal CNVs are highly aggressive lesions that demonstrate poor response despite combined therapy using PDT and Macugen.

Cited by 12 publications

References 5 publications

Current status of anti-vascular endothelial growth factor therapy in Europe

Current status of anti-vascular endothelial growth factor therapy in Europe

Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy

Pegaptanib Versus Combined Pegaptanib and Photodynamic Therapy for Neovascular Age-Related Macular Degeneration

Contact Info

Product

Resources

About